103 related articles for article (PubMed ID: 18780198)
1. A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971.
Coudert B; Focan C; Genet D; Giacchetti S; Cvickovic F; Zambelli A; Fillet G; Chollet P; Amoroso D; Van Der Auwera J; Lentz MA; Marreaud S; Baron B; Gorlia T; Biville F; Lévi F
Chronobiol Int; 2008 Sep; 25(5):680-96. PubMed ID: 18780198
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Delozier T; Guastalla JP; Yovine A; Levy C; Chollet P; Mousseau M; Delva R; Coeffic D; Vannetzel JM; Zazzi ES; Brienza S; Cvitkovic E
Anticancer Drugs; 2006 Oct; 17(9):1067-73. PubMed ID: 17001180
[TBL] [Abstract][Full Text] [Related]
3. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice.
Filipski E; Amat S; Lemaigre G; Vincenti M; Breillout F; Lévi FA
J Pharmacol Exp Ther; 1999 Apr; 289(1):231-5. PubMed ID: 10087009
[TBL] [Abstract][Full Text] [Related]
4. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
Lévi F; Focan C; Karaboué A; de la Valette V; Focan-Henrard D; Baron B; Kreutz F; Giacchetti S
Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1015-35. PubMed ID: 17692427
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
Rezai K; Urien S; Isambert N; Roche H; Dieras V; Berille J; Bonneterre J; Brain E; Lokiec F
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
[TBL] [Abstract][Full Text] [Related]
8. Quality of life analyses from vinorelbine (Navelbine) clinical trials of women with metastatic breast cancer.
Bertsch LA; Donaldson G
Semin Oncol; 1995 Apr; 22(2 Suppl 5):45-53; discussion 53-4. PubMed ID: 7740333
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of potential interaction between vinorelbine and clarithromycin.
Yano R; Tani D; Watanabe K; Tsukamoto H; Igarashi T; Nakamura T; Masada M
Ann Pharmacother; 2009 Mar; 43(3):453-8. PubMed ID: 19261952
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer.
Cassier PA; Ray-Coquard I; Sunyach MP; Lancry L; Guastalla JP; Ferlay C; Gomez F; Curé H; Lortholary A; Claude L; Blay JY; Bachelot T
Cancer; 2008 Nov; 113(9):2532-8. PubMed ID: 18780315
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
[TBL] [Abstract][Full Text] [Related]
12. Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study.
Bollet MA; Sigal-Zafrani B; Gambotti L; Extra JM; Meunier M; Nos C; Dendale R; Campana F; Kirova YM; Diéras V; Fourquet A;
Eur J Cancer; 2006 Sep; 42(14):2286-95. PubMed ID: 16893641
[TBL] [Abstract][Full Text] [Related]
13. Vinorelbine as first-line or second-line therapy for advanced breast cancer: a Phase I-II trial by the Danish Breast Cancer Co-operative Group.
Langkjer ST; Ejlertsen B; Mouridsen H; Andersen J; Nielsen MM; Møller KA; Madsen EL; Haarh V;
Acta Oncol; 2008; 47(4):735-9. PubMed ID: 18465342
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.
Ma CD; Chen CM; Chen XS; Liu GY; Di GH; Wu J; Lu JS; Yang WT; Chen JY; Shao ZM; Shen ZZ; Shen KW
Anticancer Res; 2008; 28(5B):3093-7. PubMed ID: 19031963
[TBL] [Abstract][Full Text] [Related]
16. Circadian time-dependent differences in murine tolerance to the antihistaminic agent loratadine.
Dridi D; Boughattas NA; Aouam K; Reinberg A; Ben Attia M
Chronobiol Int; 2005; 22(3):499-514. PubMed ID: 16076650
[TBL] [Abstract][Full Text] [Related]
17. The effects of food on the pharmacokinetic profile of oral vinorelbine.
Bugat R; Variol P; Roché H; Fumoleau P; Robinet G; Senac I
Cancer Chemother Pharmacol; 2002 Oct; 50(4):285-90. PubMed ID: 12357302
[TBL] [Abstract][Full Text] [Related]
18. Maintenance treatment in metastatic breast cancer.
Sánchez-Muñoz A; Pérez-Ruiz E; Ribelles N; Márquez A; Alba E
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1907-12. PubMed ID: 19046111
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.
Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Mar; 55(3):337-41. PubMed ID: 17126951
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
